Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (352)	7/26/1999 10:08:00 PM
From: Herc	Read Replies (3) \| Respond to of 399

Upon reviewing the investor info. packet the company sent me, it is true that ARQL's deal with Pfizer has no royalty agreements. It's strictly contract work. They needed the guaranteed revenue without the risk of waiting years for royalties. But it does have a royalty arrangement with J & J and Amersham Pharmacia Biotech. So calling ARQL an embryonic SEPR ain't that far-fetched, all you smarty-pants (PhD's) out there. Hey, I took chemistry and organic chemistry in college and received one A and three B's in the four semesters. Chemistry was never my strong suit though. This seems like one to buy a few thousand dollars worth and then forget about.